Antithrombotic effect of tissue factor inhibition by inactivated factor VIIa: An ex vivo human study

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 22, Issue 6, 2002, Pages 1036-1041

  Lev, Eli I ^a   Marmur, Jonathan D ^a   Zdravkovic, Milan ^a   Osende, Julio I ^a   Robbins, Jonathan ^a   Delfin, Jenny A ^a   Richard, Merwin ^a   Erhardtsen, Elisabeth ^a   Thomsen, Mikael S ^a   Lincoff, A Michael ^a   Badimon, Juan J ^a  

^a MOUNT SINAI MEDICAL CENTER   (United States)

Author keywords

Factor VIIa; Fibrin; Platelets; Thrombus formation; Tissue factor

Indexed keywords

ACETYLSALICYLIC ACID; BLOOD CLOTTING FACTOR 7A; CLOPIDOGREL; HEPARIN; THROMBOPLASTIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FIBRIN DEPOSITION; HUMAN; MALE; PRIORITY JOURNAL; PROTEIN BINDING; SHEAR RATE; THROMBOSIS; THROMBUS; TRANSLUMINAL CORONARY ANGIOPLASTY;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANIMALS; BLOOD COAGULATION TESTS; CORONARY STENOSIS; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FACTOR VIIA; FEMALE; FIBRIN; FIBRINOLYTIC AGENTS; HUMANS; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED; PERFUSION; PLATELET FUNCTION TESTS; RECOMBINANT FUSION PROTEINS; SWINE; THROMBOPLASTIN; THROMBOSIS;

EID: 0036078127     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.0000019732.25208.B8     Document Type: Article

References (38)

1. How does angioplasty work?: Serial analysis of human iliac arteries using intravascular ultrasound
2. Thrombosis of a flexible coil coronary stent: Frequency, predictors and clinical outcome
3. Balloon angioplasty: Natural history of the patho-physiologic response to injury in a pig model
4. Thrombin generation and fibrin formation following injury to rabbit neointima
5. The three processes leading to post PTCA restenosis: Dependence on the lesion substrate
6. Inhibition of tissue factor-mediated coagulation markedly attenuates stenosis after balloon-induced arterial injury in minipigs
7. Influence of blockade at specific levels of the coagulation cascade on restenosis in a rabbit atherosclerotic femoral artery injury model
8. Neointimal thickening after severe coronary artery injury is limited by short-term administration of a factor Xa inhibitor: Results in a porcine model
9. Prolonged thrombin inhibition reduces restenosis after balloon angioplasty in porcine coronary arteries
10. Tissue factor: Then and now
11. Tissue factor pathway inhibitor and the revised theory of coagulation
12. Hirudin reduces tissue factor expression in neointima after balloon injury in rabbit femoral and porcine coronary arteries
13. Tissue factor is rapidly induced in arterial smooth muscle after balloon injury
14. Antithrombotic efficacy of inactivated active site recombinant factor VIIa is shear dependent in human blood
15. The interaction of human factor VIIa with tissue factor
16. Incorporation of an active site inhibitor in factor VIIa alters the affinity for tissue factor
17. Active site-inhibited factor VIIa blocks tissue factor activity and prevents arterial thrombus formation in baboons
18. Inactivated factor VII exercises a powerful antithrombotic activity in an experimental model of recurrent arterial thrombosis
19. Antithrombotic and antilesion benefits without hemorrhagic risks by inhibiting tissue factor pathway
20. Antithrombotic effects of recombinant human, active site-blocked factor VIIa in a rabbit model of recurrent arterial thrombosis
21. Active-site blocked factors VIIa and IXa differentially inhibit fibrin formation in a human ex vivo thrombosis model
22. Pharmacokinetics and safety of FFR-rFVIIa after single doses in healthy subjects
23. First clinical investigation of a tissue-factor inhibitor administered during percutaneous coronary revascularization: A randomized, double-blinded, dose-escalation trial: Assessing safety and efficacy of FFR-rFVIIa in percutaneous transluminal coronary angioplasty (ASIS) trial
24. Characterization of the relative thrombogenicity of atherosclerotic plaque components: Implications for consequences of plaque rupture
25. Characterization of a tubular flow chamber for studying platelet interaction with biologic and prosthetic materials: Deposition of indium 111-labeled platelets on collagen, subendothelium, and expanded polytetrafluoroethylene
26. Hyperlipidemia and coronary disease: Correction of the increased thrombogenic potential with cholesterol reduction
27. Antithrombotic effects of abciximab
28. Effect of an eccentric severe stenosis on fibrin(ogen) deposition on severely damaged vessel wall in arterial thrombosis: Relative contribution of fibrin(ogen) and platelets
29. Tissue factor-induced coagulation triggers platelet thrombus formation as efficiently as fibrillar collagen at arterial blood flow conditions
30. A new method for quantitative analysis of whole blood platelet interaction with extracellular matrix under flow conditions
31. Testing platelet activation with a shear-dependent platelet function test versus aggregation-based tests: Relevance for monitoring long-term glycoprotein IIb/IIIa inhibition
32. Tissue factor modulates the thrombogenicity of human atherosclerotic plaques
33. The coagulation cascade: Initiation, maintenance and regulation
34. A monoclonal antibody against rabbit tissue factor inhibits thrombus formation in stenotic injured rabbit carotid arteries
35. Local inhibition of tissue factor reduces the thrombogenicity of human atherosclerotic plaques: Effects of tissue factor pathway inhibitor on plaque thrombogenicity under flow conditions
36. Inhibition of tissue factor reduces thrombus formation and intimal hyperplasia after porcine coronary angioplasty
37. Heightened tissue factor associated with tissue factor pathway inhibitor and prognosis in patients with unstable angina
38. Elevated levels of shed membrane microparticles with procoagulant potential in the peripheral circulating blood of patients with acute coronary syndromes